



Published in final edited form as:

Exp Clin Psychopharmacol. 2015 December ; 23(6): 494–503. doi:10.1037/pha0000050.

Characterizing use patterns and perceptions of relative harm in dual users of electronic and tobacco cigarettes

Olga Rass, Ph.D., Lauren R. Pacek, Ph.D., Patrick S. Johnson, Ph.D., and Matthew W. Johnson, Ph.D.

Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224, USA

Abstract

Awareness and use of electronic cigarettes (e-cigarettes) is increasing. Questions regarding positive (e.g., smoking reduction/cessation) and negative (e.g., delay of cessation) potential public health consequences of e-cigarettes may be informed by studying dual users of e-cigarettes and tobacco cigarettes. A cross-sectional online survey assessed demographics, product use patterns, and beliefs about relative product benefits and harms among dual users ($n = 350$) in the United States using the website Amazon Mechanical Turk (MTurk). Compared to tobacco cigarettes, e-cigarettes were used less often and were associated with lower dependence. Participants reported a 30% reduction in self-reported tobacco cigarette smoking since beginning to use e-cigarettes. Reported primary reasons for e-cigarette use were harm reduction and smoking cessation. E-cigarette use was reported as more likely in settings with smoking restrictions and when others' health could be adversely affected. Conversely, participants reported having used tobacco cigarettes more often than e-cigarettes in hedonic situations (e.g., after eating, drinking coffee or alcohol, or having sex), outdoors, or when stressed. Participants were twice as likely to report wanting to quit tobacco cigarettes compared to e-cigarettes in the next year and intended to quit tobacco cigarettes sooner. Tobacco cigarettes were described as more harmful and addictive, but also more enjoyable than e-cigarettes. Participants provided evidence consistent with both positive and negative public health consequences of e-cigarettes, highlighting the need for experimental research, including laboratory studies and clinical trials. Policies should consider potential public health benefits of e-cigarettes, in addition to potential harms.

Keywords

e-cigarette; smoking; cigarette; use patterns; dual use

Traditional (combustible) tobacco cigarette use is responsible for staggering morbidity and mortality in the United States and is a significant economic burden (U.S. Department of Health and Human Services, 2014). Electronic cigarettes or “e-cigarettes” are an evolving

and increasingly prevalent technology with the potential to substitute for tobacco cigarettes. E-cigarettes work by heating a solution that contains nicotine to produce an aerosol or “vapor” to be inhaled or “vaped” by the user. E-cigarette use is accelerating rapidly: National tobacco use surveys report more than a two-fold increase in e-cigarette use and/or experimentation among youth and adult smokers over a 1-year period, as well as a three-fold increase among youth never-smokers of tobacco cigarettes (Bunnell et al., 2015; King, Alam, Promoff, Arrazola, & Dube, 2013; Pearson, Richardson, Niaura, Vallone, & Abrams, 2012; Zhu et al., 2013). Financial analysts estimate that sales of e-cigarette and related products have reached \$2.5 billion per year and predict that sales will surpass tobacco cigarette sales by 2024 (Herzog, Gerberi, & Scott, 2014).

The increasing popularity of e-cigarettes has sparked debate among public health and tobacco control communities regarding the potential public health impact of these products. Critics are concerned about potential health risks, for example, the production of toxins during vaporization (Kosmider et al., 2014). Questions also remain as to whether e-cigarettes might prevent smoking cessation or cause relapse by presenting a purportedly healthier option, as with “light” cigarettes. “Light” cigarettes, which delivered less tar and nicotine than regular cigarettes when tested on machine inhalation systems, were purported to be healthier than regular cigarettes. However, research eventually showed that these “light” cigarettes did not afford reduced harm, and likely caused substantial public health harm by maintaining smoking behavior in many health-concerned individuals who would have otherwise quit smoking (Grana, Benowitz, & Glantz, 2014; Warner, 2005). E-cigarettes may also pose a risk for relapse in former smokers and for smoking initiation in nonsmokers (e.g., for novelty or cognitive-enhancing properties of nicotine without risk from tobacco smoking), although there is no current evidence to support these claims. Additional concerns include a potential return to the social acceptability of smoking-like behavior, which could increase nonsmoking youth initiation of smoking or vaping, renormalization of tobacco consumption in indoor workplaces and public spaces, and the use of e-cigarettes to administer other drugs (e.g., cannabis, cocaine) (Grana et al., 2014; Kinnunen et al., 2014; Pepper et al., 2013).

In contrast, supporters of e-cigarettes assert that e-cigarettes provide less toxin exposure than tobacco cigarettes (Burstyn, 2014; Cahn & Siegel, 2011; Farsalinos & Palosa, 2014), and suggest that these products will aid in smoking reduction and cessation and inspire new quit attempts in tobacco cigarette smokers by serving as nicotine replacement products. Increased acceptability of e-cigarettes over currently FDA-approved forms of nicotine replacement (e.g., gum, patch) may render e-cigarettes substantially more effective at reducing smoking at the population level than traditional nicotine replacement medications (Barbeau, Burda, & Siegel, 2013; Steinberg et al., 2014). Even if e-cigarettes cause some level of health harm and deter some users from quitting nicotine-containing products altogether, e-cigarettes could still result in net public health benefit considering that the overwhelming rate of death and disease from tobacco cigarettes may be decreased (Nitzkin, 2014).

Current tobacco cigarette smokers who also use e-cigarettes (i.e., “dual users”) are informative to addressing both the positive (e.g., smoking reduction/cessation) and negative

(e.g., delay of cessation) public health claims regarding e-cigarettes (Walton et al., 2015). Moreover, although dual users constitute the majority of e-cigarette users (e.g., Giovenco, Lewis, & Delnevo, 2014; Sutfin, McCoy, Morrell, Hoepfner, & Wolfson, 2013), surveys of e-cigarette use have only recently focused on dual users (Farsalinos, Romagna, & Voudris, 2015; Rutten et al., 2015). A potential limitation of one of these studies (Farsalinos et al.) was that two-thirds of participants were recruited from e-cigarette forums, which may have resulted in an oversampling of individuals with a positive bias toward e-cigarettes. Moreover, Farsalinos et al.'s sample was largely European, making results potentially less representative of dual use in the United States, where increased tobacco control activity may influence user attitudes about smoking and related behaviors (Shiffman, 2009). By contrast, Rutten et al. (2015) used a panel-based approach to survey U.S. dual users. Unfortunately, e-cigarette use duration and nicotine content were not measured, resulting in a sample that potentially included e-cigarette users who were relatively inexperienced or used e-cigarettes containing zero nicotine. The present online survey was conducted concurrently with the Rutten et al. survey, and like their study recruited dual users in the United States to describe use patterns and harm perceptions of e-cigarettes and tobacco cigarettes. However, unlike Rutten et al., our sample included only dual users who had substantial experience with both products (i.e., at least 3 months use and past-week use) and used only nicotine-containing e-cigarettes, characteristics that we believe are critical for understanding public health consequences of dual use of e-cigarettes and tobacco cigarettes.

Methods

Participants

Participants were dual users of e-cigarettes and tobacco cigarettes who were registered on Amazon Mechanical Turk (MTurk), a crowdsourcing Internet marketplace that has been used extensively for research (e.g., Adkison, O'Connor, Chaiton, & Schwartz, 2015; Carter, DiFeo, Bogie, Zhang, & Sun, 2014; Johnson et al., 2015). Dual use of e-cigarettes and tobacco cigarettes was defined as use of e-cigarettes and tobacco cigarettes for 3 months, each; use of e-cigarettes and smoking of tobacco cigarettes in the past week; and use of a nicotine-containing e-cigarette. Participants were required to have a 95% or higher approval rating on MTurk, be 18 years of age, and reside in the United States (confirmed during initial registration on MTurk). Participation was voluntary and anonymous (no name or IP address were recorded). The Institutional Review Board at Johns Hopkins University approved this study.

Materials

Surveys were hosted by Qualtrics (Provo, UT). The screening questionnaire included the survey description (e.g., purpose of the study, confidentiality and anonymity of responses, compensation), and questions determining demographics and use status of e-cigarettes and tobacco cigarettes. Demographic questions were included to obscure inclusion criteria based on dual use. If a participant met inclusion criteria, he or she was given a code to access the password-protected survey.

Participants were asked about e-cigarette and tobacco cigarette use patterns as well as perceived harm and legality of these products (survey available in Supplemental Materials). Dependence was assessed using the *Fagerström* Test for Cigarette Dependence (FTCD; Fagerström, 2012; Heatherton, Kozlowski, Frecker, & Fagerström, 1991) to examine tobacco cigarettes, and a modified version to examine dependence to e-cigarettes; the FTCD was modified by substituting the word “e-cigarette” for any instance of “cigarette” and substituting “using” for any instance of “smoking.”

Procedure

The survey was advertised on MTurk with the title, “Survey about e-cigarettes and decision making.” Prior to completing the survey, participants were instructed to complete the brief screening questionnaire to determine qualification status. If a participant qualified, he/she completed the survey in a new tab of the active Internet browser. Participants were instructed to complete the survey in one sitting. Once finished with the survey, participants were instructed to enter their unique MTurk identification number. Upon returning to MTurk, participants were prompted to enter their identification number into a text box to verify that they had completed the survey. Participants whose identification number matched the identification number submitted at the end of the survey were paid \$1. The survey was active from May 7–20, 2014.

Two tactics were employed with the intention of improving the quality of participant responses. First, in the MTurk advertisement and survey descriptions, participants were instructed that paying attention during the survey and answering questions carefully could potentially result in a \$0.25 bonus payment. Second, distractor questions and attention check questions were included at multiple stages. For example, in one question, participants were asked to select adjectives consistent with their current mood state, but embedded in the instructions for the question was a prompt to select “none of the above” as the response. Participants who indicated inattention (e.g., failed a distractor question; provided internally inconsistent answers) were excluded from all analyses.

Data Analysis

Descriptive analyses (e.g., percentage endorsing a given item) were used to characterize demographic and categorical items. In most cases, data pertaining to e-cigarette and tobacco cigarette use patterns were non-normally distributed; summary data for these variables are therefore reported as medians with interquartile ranges (IQR). Non-normally distributed data also necessitated the use of Spearman rank-order correlations, which measured the relationship between product use duration or frequency and product use behavior for e-cigarettes and tobacco cigarettes. Differences in daily tobacco cigarette use before and after e-cigarette initiation were examined using a Wilcoxon signed-rank test.

In total, 400 participants completed the survey. Data from 50 participants were excluded based on inattention ($n = 12$) or failure to meet dual-use inclusion criteria despite having qualified via the screening questionnaire ($n = 38$). All analyses were conducted using data from the remaining 350 participants.

Results

Demographic Characteristics

Table 1 shows demographic characteristics of the sample. The mean participant age was 32 years ($SD = 10$; $Range = 18-70$), and 53% were male, 83% were Caucasian, and 85% were non-Hispanic. The most commonly endorsed range of annual income was \$35,000 (48%) and most participants were employed full time (53%). Most had never been married (53%) and 83% had completed at least some college. Although most participants (57%) reported never having received a diagnosis of a psychiatric disorder, 20% and 23% reported a diagnosis of one or multiple disorders in their lifetime, respectively; these rates are consistent with past research on psychiatric diagnosis rates in smokers (Lawrence, Mitrou, & Zubrick, 2009; Minichino et al., 2013).

Use Patterns and Dependence

Tables 2 and 3 describe tobacco cigarette and e-cigarette use patterns and dependence, respectively. Participants reported smoking tobacco cigarettes more times per day and more days per week than using e-cigarettes. Compared with e-cigarette use, tobacco cigarette use was associated with higher dependence scores, less time to first use of the day, greater reluctance to give up the first use of the day, greater likelihood of daily use, and stronger cravings. The percentage of participants reporting daily use was lower for e-cigarettes (47%) than tobacco cigarettes (86%).

E-cigarette use was associated with a significant reduction in self-reported tobacco cigarette use. Since initiation of e-cigarette use, the median number of tobacco cigarettes smoked per day (CPD) decreased significantly from 10 to 7 CPD (30% reduction), $n = 346$, $Z = -10.41$, $p < .001$. For participants whose CPD changed after e-cigarette use initiation ($n = 189$), most (83%) agreed that e-cigarette use played a role in this change. Half of the sample reported reductions in CPD, with a median reduction of 5 CPD (IQR = 3 to 10) from a median of 15 to 6 CPD. An almost equal percentage (45%) of participants reported no change in CPD, remaining at median of 10 CPD. Only 5% of participants reported an increase in CPD, with a median increase of 4 CPD (IQR = 1 to 7) from a median of 3 to 10 CPD. An exploratory comparison of daily compared to nondaily e-cigarette users found minimal differences in tobacco use behavior, with the exception of change in median tobacco CPD: following e-cigarette initiation, daily users ($n=91$) decreased from 15 to 8 CPD (47% reduction) compared to non-daily users ($n=256$), who decreased from 10 to 7 CPD. An independent samples t -test confirmed that daily users had significantly greater reduction in CPD than non-daily users, $t(343)=7.607$, $p<.001$.

Table 4 shows results of correlational analyses between aspects of e-cigarette and tobacco cigarette use. Duration of e-cigarette use was positively and significantly correlated with duration of tobacco use. More frequent use of e-cigarettes was significantly associated with lower current CPD and greater decreases in CPD and days smoked per week following initiation of e-cigarette use. Longer duration of tobacco cigarette use was significantly correlated with a smaller change in CPD. Frequency of tobacco cigarette use was significantly correlated with the lower dependence (modified FTCD score) for e-cigarettes.

Past Quit Attempts and Intention to Quit

Sixty-eight percent of participants reported a past serious quit attempt for tobacco cigarettes that lasted at least 24 hours and 41% reported a serious quit attempt in the past year. Sixty-one percent of participants reported personally knowing someone who had quit using tobacco cigarettes for at least one month with the help of e-cigarettes. Twice as many participants were planning to quit using tobacco cigarettes (73%) compared to planning to quit e-cigarettes (36%) in the next year.

Sixty-eight percent of participants reported having used nicotine replacement therapy (NRT), other medications (e.g., varenicline, bupropion), or other methods (e.g., counseling, quitline) to assist in quitting tobacco cigarettes. Notably, 20% of participants reported having used NRT, varenicline, or bupropion for unspecified reasons other than to quit smoking. Of participants reporting past use of NRT to quit smoking, 27% reported having used only one method, whereas 33% reported having used more than one method. The most commonly used NRT products were nicotine gum (39%) and nicotine patch (38%).

Product Experience

Regarding experience with tobacco products, most participants reported most commonly using commercially available, machine-rolled tobacco cigarettes (91%) and cigarettes without menthol flavor (59%). In the past 30 days, 40% of participants reported using one or more other tobacco products; hookah (52%) and cigars (40%) were most likely to be used, whereas chew was used most frequently ($Mdn = 6$ days) (Table 5). Most participants either did not know if their e-cigarette model was modified (43%) or reported not using a modified product (37%). Many participants reported not using menthol or other flavored e-liquid (53%); however, those who reported having tried flavored e-liquid (59%) continued to use it (79%).

Twenty-seven participants (8%) reported using products other than e-liquid or nicotine in an e-cigarette. Cannabis was the most commonly used substance ($n = 22$), followed by “synthetic cannabis (e.g., K2, Spice)” ($n = 3$), methamphetamine ($n = 2$), “bath salt compounds (e.g., MDPV, mephedrone)” ($n = 2$), and “prescription pain pills (e.g., Vicodin, Oxycontin)” ($n = 1$). The 22 participants reporting cannabis use in e-cigarettes reported using it this way a median of 10 times in their lifetime ($IQR = 2.75–20$). Twenty of these participants reported being “able to get high,” and 14 reported continued use of this method. Other drugs were associated with success in achieving a “high” (“bath salt” compounds: $n = 2$; methamphetamine: $n = 1$, synthetic cannabis: $n = 1$), but minimal continuation of use.

Use Reasons and Settings

Participants were asked to endorse all applicable reasons for their use of e-cigarettes (Table 6). Among the most popular reasons for e-cigarette use was the belief that they are less harmful to their health than tobacco cigarettes (64%), that e-cigarettes were used to deal with cravings (57%), and the belief that e-cigarettes are less harmful to others than tobacco cigarettes (52%). When asked to identify the single-most important reason for e-cigarette use, participants most often endorsed that they believed that e-cigarettes were less harmful

to their health than tobacco cigarettes (25%). The second most commonly endorsed important reason for use was to cut down smoking in preparation for a quit attempt (21%).

As shown in Figure 1, participants reported a greater likelihood of using e-cigarettes than tobacco cigarettes indoors (75%), in a restaurant (49%), in a car (49%), at the airport (46%), around family in general (46%), and at work (45%). By comparison, tobacco cigarettes were more likely than e-cigarettes to be used in settings with alcohol (69%), outdoors (65%), when stressed or anxious (61%), after eating (53%), when drinking coffee (53%), and after having sex (52%). E-cigarette use was reported to be more likely than tobacco cigarette use around children or pregnant women, with 45% of participants reporting being more likely to use e-cigarettes than tobacco cigarettes in those settings and 42% reporting using neither product.

Harm Perceptions

Among participants who agreed with the statement that e-cigarettes and tobacco cigarettes are enjoyable ($n = 281$), 63% reported that e-cigarettes were less enjoyable than tobacco cigarettes. Among participants who agreed with the statement that e-cigarettes and tobacco cigarettes are addictive ($n = 238$), 57% reported that e-cigarettes were less addictive than tobacco cigarettes. Of the whole sample, 30% reported that e-cigarettes were not at all addictive. On average, participants rated e-cigarettes as having a lower harm on an 11-point Likert-type scale than tobacco cigarettes for harming self and others (Table 7). When asked if one product was more harmful than the other, more participants reported being unsure about the dangers of e-cigarettes (22%) than tobacco cigarettes (2%). Eighty-seven percent endorsed the belief that tobacco cigarettes are much more (57%) or somewhat more (30%) harmful than e-cigarettes. Over half (59%) of participants agreed with the statement that NRT was equally as harmful as e-cigarettes (the most commonly endorsed response). The analogous statement regarding e-cigarettes being equally as harmful as non-NRT medications was also the most commonly endorsed response (37%).

Gender Effects

Gender analyses showed minor effects on use patterns and perceptions of relative harm. Females reported a longer duration of tobacco cigarette use than males, $t(348) = -2.1, p = .03$, and reported using tobacco cigarettes on more days per week than males both before, $t(348) = -0.1, p = .04$, and after e-cigarette initiation, $t(346) = -3.3, p = .001$. No gender differences were detected for quit intent regarding e-cigarettes or tobacco cigarettes. Males and females also did not differ on reported harmfulness of e-cigarettes. Compared to males, females reported greater perceived harm from tobacco cigarettes to self, $t(348) = -4.2, p < .001$, and others, $t(348) = -4.3, p < .001$. Females were more likely than males to endorse using e-cigarettes to deal with tobacco cravings, $X^2(1, N = 350) = 14.6, p < .001$, to quit smoking or avoid relapsing, $X^2(1, N = 350) = 4.2, p = .04$, and because e-cigarettes are cheaper than tobacco cigarettes, $X^2(1, N = 350) = 5.7, p = .02$. Gender differences in reported use likelihood were found for several variables. Specifically, a greater percentage of males than females reported being more likely to use e-cigarettes over tobacco cigarettes at home, and a greater percentage of females than males reported equal likelihood of using either type of product at home, $X^2(3, N = 350) = 8.7, p = .03$. A greater percentage of males

than females reported being more likely to use e-cigarettes over tobacco cigarettes upon waking in the morning, and a greater percentage of females than males reported using tobacco cigarettes over e-cigarettes upon waking in the morning, $X^2(3, N = 350) = 11.4, p = .01$. A greater percentage of males than females reported being more likely to use e-cigarettes over tobacco cigarettes outdoors, and a greater percentage of females than males reported equal likelihood of using either product outdoors, $X^2(3, N = 350) = 10.0, p = .01$. Despite these differences, both male and female participants reported the greatest likelihood of using e-cigarettes at home and using tobacco cigarettes upon waking in the morning and outdoors.

Discussion

The present research sought to characterize e-cigarette and tobacco cigarette use patterns and relative harm perceptions in current dual users of both products. We observed several noteworthy findings regarding dual use with potential implications for public health. Each will be discussed in turn.

The first major finding was that more frequent e-cigarette use (i.e., more days per week) was associated with fewer CPD and greater decrease in tobacco cigarette use (CPD and days per week), a result suggestive of a systematic effect of e-cigarettes substituting for smoking and one that is consistent with previous findings (Farsalinos et al., 2015). Cross-sectional studies of smokers outside of a quit context found a reduction in CPD, suggesting that e-cigarettes may aid in reduction or cessation efforts (Adkison et al., 2013; Etter & Bullen, 2011a; Lechner et al., 2015; Rutten et al., 2015). Dual users in the Rutten et al. (2015) sample reported smoking “fewer cigarettes” (54.1%), “about the same number of cigarettes” (40.6%), or reported smoking “more cigarettes” (1.6%) following e-cigarette initiation; these findings were very similar to our survey sample, which reported a decrease (50%), no change (45%), or increase (5%) in CPD. Smoking reduction may be associated with an intermediate stage between regular use and total cessation, which has been shown to increase the motivation of daily heavy smokers to quit (Cheong, Yong, & Borland, 2007; Schane, Ling, & Glantz, 2010). Therefore, e-cigarette-related reductions in smoking may present an opportunity for re-engaging smokers in cessation efforts (e.g., counseling, medication), which can double or triple the chances for quitting (Centers for Disease Control and Prevention, 2011; Hughes, 2003; Rutten et al., 2015). Given the fact that reduction of cigarette smoking is associated with some reduction in morbidity (Gerber, Myers, & Goldbourt, 2012; Joseph et al., 2008; Lee, 2013; Tverdal & Bjartveit, 2006), a promising outcome from our study is that we observed a group-level decrease in the number of cigarettes smoked per day in our sample of dual users, despite a minority endorsing smoking cessation as a reason for e-cigarette use.

In contrast to concerns that e-cigarette use could promote initiation to tobacco cigarette smoking, we observed initiation of tobacco use after e-cigarette use in only one of 350 participants, suggesting a low rate of transitioning from e-cigarettes to tobacco cigarettes. This finding is consistent with previous results showing higher rates of current and ever use of e-cigarettes among current cigarette smokers than non-smokers (Czoli, Hammond, & White, 2014; McMillen, Maduka, & Winickoff, 2012; Nitzkin, 2014; Pearson et al., 2012;

Pepper et al., 2013; Regan, Promoff, Dube, & Arrazola, 2013; Sutfin et al., 2013). Finally, our data also suggest that only a small percentage of the sample modified their e-cigarette or used non-nicotine drugs in their e-cigarette device. Therefore, it appears that use of other drugs in these devices is a relatively minor issue at this time.

A second major finding was that a large percentage of dual users reported intending to quit smoking tobacco cigarettes within the next year, and many had previous experience with one or more cessation products (e.g., NRTs, cessation pharmacotherapy). We found that 68% of dual users reported a serious quit attempt (\geq 24 hours) and 41% planned to quit in the next 6 months, consistent with Rutten et al., who found 65% of dual users were considering quitting smoking cigarettes or cigars in the next 6 months. Although limited, there is some evidence to support e-cigarettes as helping to reduce smoking rates (Bullen et al., 2013; Caponnetto et al., 2013; McRobbie, Bullen, Hartmann-Boyce, & Hajek, 2014) and motivate new cessation attempts. For instance, one randomized controlled trial found that e-cigarettes performed similarly to nicotine patch with respect to six-month quit rates, and were well tolerated (Bullen et al., 2013). Additionally, e-cigarette appeal and client motivation may provide better treatment compliance compared to pharmacotherapies and NRT products due to sensorimotor characteristics, socioeconomic factors, convenience, and mild side effects (Caponnetto et al., 2013; Farsalinos, Romagna, Tsiaparos, Kyrzopoulos, & Voudris, 2014). The modest success rates of NRT products may be improved by adjunctive use of low-nicotine or nicotine-free e-cigarettes as a cessation tool (Moore et al., 2009; Walker et al., 2012). It is worth noting that not all e-cigarette users are interested in smoking cessation or reduction. In these individuals, e-cigarettes may potentially facilitate smoking and reduce motivation for eventual cessation, although there is currently no evidence to support this.

Third, similar to previous research, participants reported their primary reasons for using e-cigarettes as being less harmful to one's health (relative to tobacco cigarettes) and to cut down smoking tobacco cigarettes in preparation for a quit attempt (Adkison et al., 2013; Farsalinos et al., 2014; Goniewicz, Lingas, & Hajek, 2013; Rutten et al., 2015). Despite offering fewer and different options as use reasons, Rutten et al. (2015), found that dual users endorsed reasons for e-cigarette use related to smoking reduction, smoking cessation, and reduction of health risks; they did not ask about one's most important reason for use. Participants reported being more likely to use e-cigarettes in settings where smoking may be restricted (e.g., in a restaurant, indoors), providing some confirmation that e-cigarettes are being used to comply with smoke-free laws. Participants were also more likely to use e-cigarettes when concerned about adverse effects of smoking on others' health. The sample largely endorsed either not using any product, or using e-cigarettes only, around children or pregnant women. Further research is needed to evaluate the effects of acute and chronic exposure to nicotine and other low-level toxins from second- or third-hand vapor in vulnerable populations (e.g., infants and children, pregnant women, individuals with chronic illness) to develop evidence-based health policies and recommendations (Ballbe et al., 2014; Collaco, Drummond, & McGrath-Morrow, 2015; Durmowicz, 2014). Finally, participants reported being more likely to use tobacco cigarettes in hedonic situations, when there were no use restrictions, or when stressed/anxious, suggesting that situations such as these might be the most difficult circumstances for dissuading cigarette smoking. Longitudinal studies (e.g., Population Assessment of Tobacco and Health; <https://pathstudyinfo.nih.gov>) and

studies with long retrospective report would be better suited to measure changes in use motives (e.g., desire to quit or reduce smoking) and public health outcomes, such as delayed cessation.

Lastly, with respect to perceptions of relative harm, participants reported that they perceived e-cigarettes to be safer and less addictive than tobacco cigarettes, a finding consistent with previous reports (e.g., Amrock, Zakhar, Zhou, & Weitzman, 2015; Farsalinos et al., 2015; Goniewicz, Lingas, et al., 2013; Pearson et al., 2012). Dual users in our sample also reported that e-cigarettes were less harmful than pharmacotherapy for smoking cessation, and were no more harmful than NRT (e.g., patch, gum). Although no studies of long-term safety of e-cigarettes are available, recently proposed federal regulations may reduce some of the heterogeneity in e-cigarettes that contributes to significant health concerns with regard to poor quality control (e.g., inaccurate labeling of nicotine content, variable nicotine delivery) and health risks (e.g., nicotine toxicity, low-level toxic contaminants and carcinogens, and particulate matter) (Chatham-Stephens et al., 2014; Cheng, 2014; Grana et al., 2014; Lippi et al., 2014; Nitzkin, 2014; Pearson et al., 2012; Riker, Lee, Darville, & Hahn, 2012). Education and outreach regarding the science and regulatory status may be potentially effective in improving public knowledge regarding e-cigarettes and tobacco products.

Limitations to the study should be considered when interpreting our major findings. The survey relied on self-report, although biochemical verification of smoking behavior would have improved validity. The cross-sectional design and convenience sampling allowed for efficient data collection, but generalizability of the results may be limited due to participant self-selection and representativeness of individuals registered on MTurk relative to the population at large (e.g., education, race). Additionally, we were not able to accurately measure e-cigarette use history (e.g., progression from nicotine containing liquid to nicotine-free liquid) or e-cigarette nicotine dose. However, one benefit of recruitment via MTurk without advertising on e-cigarette forums is greater representativeness of e-cigarette users in general, reducing a potential sampling bias from e-cigarette enthusiasts. Given the length of the survey, we did not obtain information on the rate of using one or both products within a day. Future studies could explore such details as well as study more experienced e-cigarette users (e.g., Spindle, Breland, Karaoghlanian, Shihadeh, & Eissenberg, 2014) and include single-product user comparison groups. The FTCD has not been validated to assess e-cigarette nicotine dependence in dual users, and dependence on the two nicotine products was measured separately, within-subjects. The latter point can be emphasized by considering dependence measures of other drugs: for example, opioid dependence is typically not measured separately for heroin and prescription opioids. It is also important to keep in mind that the features and addictive qualities of e-cigarettes are likely to continue to change with modifications to their technology. Finally, self-report responses are susceptible to social desirability biases or errors in retrospective memory, a limitation common to survey research.

Based on our survey results, dual users of e-cigarettes and tobacco cigarettes tend to be light smokers with low-to-moderate tobacco dependence who use e-cigarettes for harm reduction and/or supplementing nicotine use in settings with smoking restrictions. To provide useful recommendations for regulatory decisions, further research is needed on this dual user

population, which is central to understanding potential positive and negative health consequences. Longitudinal studies are needed to determine evolving beliefs and use behavior, while laboratory research can provide data on abuse liability and nicotine discrimination.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- Adkison SE, O'Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong HH, Fong GT. Electronic nicotine delivery systems: International tobacco control four-country survey. *American Journal of Preventive Medicine*. 2013; 44:207–215. [PubMed: 23415116]
- Adkison SE, O'Connor RJ, Chaiton M, Schwartz R. Development of measures assessing attitudes toward contraband tobacco among a web-based sample of smokers. *Tobacco Induced Diseases*. 2015; 13:7. [PubMed: 25914612]
- Amrock SM, Zakhar J, Zhou S, Weitzman M. Perception of e-cigarette harm and its correlation with use among U.S. adolescents. *Nicotine & Tobacco Research*. 2015; 17:330–336. [PubMed: 25125321]
- Ballbè M, Martínez-Sánchez JM, Sureda X, Fu M, Pérez-Ortuño R, Pascual JA, Fernández E. Cigarettes vs. e-cigarettes: Passive exposure at home measured by means of airborne marker and biomarkers. *Environmental Research*. 2014; 135:76–80. [PubMed: 25262078]
- Barbeau AM, Burda J, Siegel M. Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: A qualitative approach. *Addiction Science & Clinical Practice*. 2013; 8:5. [PubMed: 23497603]
- Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: A randomised controlled trial. *Lancet*. 2013; 382:1629–1637. [PubMed: 24029165]
- Bunnell RE, Agaku IT, Arrazola RA, Apelberg BJ, Caraballo RS, Corey CG, King BA. Intentions to smoke cigarettes among never-smoking US middle and high school electronic cigarette users: National Youth Tobacco Survey, 2011–2013. *Nicotine & Tobacco Research*. 2015; 17:228–235. [PubMed: 25143298]
- Burstyn I. Peering through the mist: Systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. *BMC Public Health*. 2014; 14:18. [PubMed: 24406205]
- Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: A step forward or a repeat of past mistakes? *Journal of Public Health Policy*. 2011; 32:16–31. [PubMed: 21150942]
- Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. Efficiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: A prospective 12-month randomized control design study. *PLoS One*. 2013; 8:e66317. [PubMed: 23826093]
- Carter RR, DiFeo A, Bogie K, Zhang GQ, Sun J. Crowdsourcing awareness: Exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk. *PLoS One*. 2014; 9:e85508. [PubMed: 24465580]
- Centers for Disease Control and Prevention. Quitting smoking among adults—United States, 2001–2010. *MMWR: Morbidity and Mortality Weekly Report*. 2011; 60:1513–1519. [PubMed: 22071589]
- Chatham-Stephens K, Law R, Taylor E, Melstrom P, Bunnell R, Wang B, Schier JG. Notes from the field: Calls to poison centers for exposures to electronic cigarettes—United States, September 2010–February 2014. *MMWR: Morbidity and Mortality Weekly Report*. 2014; 63:292–293. [PubMed: 24699766]

- Cheng T. Chemical evaluation of electronic cigarettes. *Tobacco Control*. 2014; 23:ii11–ii17. [PubMed: 24732157]
- Cheong Y, Yong HH, Borland R. Does how you quit affect success? A comparison between abrupt and gradual methods using data from the International Tobacco Control Policy Evaluation Study. *Nicotine & Tobacco Research*. 2007; 9:801–810. [PubMed: 17654293]
- Collaco JM, Drummond MB, McGrath-Morrow SA. Electronic cigarette use and exposure in the pediatric population. *JAMA Pediatrics*. 2015; 169:177–182. [PubMed: 25546699]
- Czoli CD, Hammond D, White CM. Electronic cigarettes in Canada: Prevalence of use and perceptions among youth and young adults. *Canadian Journal of Public Health*. 2014; 105:e97–e102. [PubMed: 24886856]
- Durmowicz EL. The impact of electronic cigarettes on the paediatric population. *Tobacco Control*. 2014; 23:ii41–ii46. [PubMed: 24732163]
- Etter JF, Bullen C. Electronic cigarette: Users profile, utilization, satisfaction and perceived efficacy. *Addiction*. 2011a; 106:2017–2028. [PubMed: 21592253]
- Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. *Nicotine & Tobacco Research*. 2012; 14:75–78. [PubMed: 22025545]
- Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V. Characteristics, perceived side effects and benefits of electronic cigarette use: A worldwide survey of more than 19,000 consumers. *International Journal of Environmental Research and Public Health*. 2014; 11:4356–4373. [PubMed: 24758891]
- Farsalinos KE, Romagna G, Voudris V. Factors associated with dual use of tobacco and electronic cigarettes: A case control study. *The International Journal on Drug Policy*. 2015 Advance online publication.
- Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: A systematic review. *Therapeutic Advances in Drug Safety*. 2014; 5:67–86. [PubMed: 25083263]
- Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: A prospective cohort study. *American Journal of Epidemiology*. 2012; 175:1006–1012. [PubMed: 22306566]
- Giovenco DP, Lewis MJ, Delnevo CD. Factors associated with e-cigarette use: A national population survey of current and former smokers. *American Journal of Preventative Medicine*. 2014; 47:476–480.
- Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic cigarette use and user beliefs about their safety and benefits: An internet survey. *Drug and Alcohol Review*. 2013; 32:133–140. [PubMed: 22994631]
- Grana R, Benowitz N, Glantz SA. E-cigarettes: A scientific review. *Circulation*. 2014; 129:1972–1986. [PubMed: 24821826]
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. *British Journal of Addiction*. 1991; 86:1119–1127. [PubMed: 1932883]
- Herzog, B.; Gerberi, J.; Scott, A. Wells Fargo Securities: Equity Research. 2014. Tobacco-Nielsen C-Store Data-E-Cig \$ Sales Decline Moderates; p. 1-17.
- Hughes JR. Motivating and helping smokers to stop smoking. *Journal of General Internal Medicine*. 2003; 18:1053–1057. [PubMed: 14687265]
- Johnson PS, Herrmann ES, Johnson MW. Opportunity costs of reward delays and the discounting of hypothetical money and cigarettes. *Journal of the Experimental Analysis of Behavior*. 2015; 103:87–107. [PubMed: 25388973]
- Joseph AM, Hecht SS, Murphy SE, Lando H, Carmella SG, Gross M, Hatsukami DK. Smoking reduction fails to improve clinical and biological markers of cardiac disease: A randomized controlled trial. *Nicotine & Tobacco Research*. 2008; 10:471–481. [PubMed: 18324566]
- King BA, Alam S, Promoff G, Arrazola R, Dube SR. Awareness and ever-use of electronic cigarettes among U.S. adults 2010–2011. *Nicotine & Tobacco Research*. 2013; 15:1623–1627. [PubMed: 23449421]

- Kinnunen JM, Ollila H, El-Amin SE, Pere LA, Lindfors PL, Rimpelä AH. Awareness and determinants of electronic cigarette use among Finnish adolescents in 2013: A population-based study. *Tobacco Control*. 2014 Advance online publication.
- Kosmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, Goniewicz ML. Carbonyl compounds in electronic cigarette vapors: Effects of nicotine solvent and battery output voltage. *Nicotine & Tobacco Research*. 2014; 16:1319–1326. [PubMed: 24832759]
- Lawrence D, Mitrou F, Zubrick SR. Smoking and mental illness: Results from population surveys in Australia and the United States. *BMC Public Health*. 2009; 9:285. [PubMed: 19664203]
- Lechner WV, Tackett AP, Grant DM, Tahirkheli NN, Driskill LM, Wagener TL. Effects of duration of electronic cigarette use. *Nicotine & Tobacco Research*. 2015; 17:180–185. [PubMed: 24827788]
- Lee PN. The effect of reducing the number of cigarettes smoked on risk of lung cancer, COPD, cardiovascular disease and FEV(1)--a review. *Regulatory Toxicology and Pharmacology*. 2013; 67:372–381. [PubMed: 24013038]
- Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: Beyond science and mysticism. *Seminars in Thrombosis and Hemostasis*. 2014; 40:60–65. [PubMed: 24343348]
- McMillen R, Maduka J, Winickoff J. Use of emerging tobacco products in the United States. *Journal of Environmental and Public Health*. 2012; 2012:989474. [PubMed: 22654922]
- McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. *Cochrane Database of Systematic Reviews*. 2014; 12:CD010216. [PubMed: 25515689]
- Minichino A, Bersani FS, Calò WK, Spagnoli F, Francesconi M, Biondi M. Smoking behaviour and mental health disorders--mutual influences and implications for therapy. *International Journal of Environmental Research and Public Health*. 2013; 10:4790–4811. [PubMed: 24157506]
- Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: Systematic review and meta-analysis. *BMJ*. 2009; 338:b1024. [PubMed: 19342408]
- Nitzkin JL. The case in favor of E-cigarettes for tobacco harm reduction. *International Journal of Environmental Research and Public Health*. 2014; 11:6459–6471. [PubMed: 25003176]
- Pearson JL, Richardson A, Niaura RS, Vallone DM, Abrams DB. e-Cigarette awareness, use, harm perceptions in US adults. *American Journal of Public Health*. 2012; 102:1758–1766. [PubMed: 22813087]
- Pepper JK, Reiter PL, McRee AL, Cameron LD, Gilkey MB, Brewer NT. Adolescent males' awareness of and willingness to try electronic cigarettes. *The Journal of Adolescent Health*. 2013; 52:144–150. [PubMed: 23332477]
- Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: Adult use and awareness of the 'e-cigarette' in the USA. *Tobacco Control*. 2013; 22:19–23. [PubMed: 22034071]
- Riker CA, Lee K, Darville A, Hahn EJ. E-cigarettes: Promise or peril? *The Nursing Clinics of North America*. 2012; 47:159–171. [PubMed: 22289406]
- Rutten LJ, Blake KD, Agunwamba AA, Grana RA, Wilson PM, Ebbert JO, Leischow SJ. Use of e-cigarettes among current smokers: Associations among reasons for use, quit intentions, and current tobacco use. *Nicotine & Tobacco Research*. 2015 Advance online publication.
- Schane RE, Ling PM, Glantz SA. Health effects of light and intermittent smoking: A review. *Circulation*. 2010; 121:1518–1522. [PubMed: 20368531]
- Shiffman S. Light and intermittent smokers: Background and perspective. *Nicotine & Tobacco Research*. 2009; 11:122–125. [PubMed: 19246630]
- Spindle TR, Breland AB, Karaoghlanian NV, Shihadeh AL, Eissenberg T. Preliminary results of an examination of electronic cigarette user puff topography: The effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects. *Nicotine & Tobacco Research*. 2015; 17:142–149. [PubMed: 25239957]
- Steinberg MB, Zimmermann MH, Delnevo CD, Lewis MJ, Shukla P, Coups EJ, Foulds J. E-cigarette versus nicotine inhaler: Comparing the perceptions and experiences of inhaled nicotine devices. *Journal of General Internal Medicine*. 2014; 29:1444–1450. [PubMed: 24830741]
- Sutfin EL, McCoy TP, Morrell HE, Hoepfner BB, Wolfson M. Electronic cigarette use by college students. *Drug and Alcohol Dependence*. 2013; 131:214–221. [PubMed: 23746429]

- Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. *Tobacco Control*. 2006; 15:472–480. [PubMed: 17130377]
- U.S. Department of Health and Human Services. *The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
- Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie H, Whittaker R. The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: A randomized controlled trial. *Addiction*. 2012; 107:1857–1867. [PubMed: 22594651]
- Walton KM, Abrams DB, Bailey WC, Clark D, Connolly GN, Djordjevic MV, Hatsukami DK. NIH electronic cigarette workshop: Developing a research agenda. *Nicotine & Tobacco Research*. 2015; 17:259–269. [PubMed: 25335949]
- Warner KE. Will the next generation of "safer" cigarettes be safer? *Journal of Pediatric Hematology/Oncology*. 2005; 27:543–550. [PubMed: 16217258]
- Zhu SH, Gamst A, Lee M, Cummins S, Yin L, Zoref L. The use and perception of electronic cigarettes and snus among the U.S. population. *PLoS One*. 2013; 8:e79332. [PubMed: 24250756]

- More likely to use e-cigarettes
- More likely to use tobacco cigarettes
- Equally likely to use e-cigarettes and tobacco cigarettes
- Not applicable (don't smoke/vape in this setting)




Figure 1. Likelihood ratings of e-cigarette and tobacco cigarette use in different settings.

Table 1

Demographic Characteristics

	<i>n</i>	%
Age		
18–24	78	22%
25–39	203	58%
40–54	55	16%
55 +	14	4%
Gender		
Male	184	53%
Female	166	47%
Race		
Caucasian/White	292	83%
African American/Black	18	5%
Mixed Race	13	4%
Asian	13	4%
Native American	4	1%
Other	3	1%
I prefer not to answer	7	2%
Ethnicity		
Hispanic	39	11%
Non-Hispanic	296	85%
I prefer not to answer	15	4%
Income		
< \$25,000	89	25%
\$25,000 – \$34,999	81	23%
\$35,000 – \$49,999	56	16%
\$50,000 – \$74,999	70	20%
\$75,000	47	13%
I prefer not to answer	7	2%
Marital Status		
Married	114	33%
Divorced/Separated/Widowed	52	15%
Never been married	184	53%
Education		
No high school diploma	2	1%
High school or GED	44	13%
Post-high school trade/vocational training	15	4%
Some college credit	118	34%
College degree (Associate, Bachelor's)	153	44%
Graduate or Professional degree	17	5%
I prefer not to answer	1	0%

	<i>n</i>	%
Employment		
Full Time	184	53%
Part Time	76	22%
Unemployed	50	14%
Student	40	11%
History of Psychiatric Diagnosis		
Never	199	57%
One disorder	70	20%
More than one disorder	81	23%
Anxiety	94	27%
Depression	105	30%
Bipolar Disorder	28	8%
Schizophrenia or Schizoaffective Disorder	2	1%
Attention Deficit Hyperactivity Disorder (ADHD)	22	6%
Post Traumatic Stress Disorder (PTSD)	29	8%
Other	4	1%

Note. Percentages may not sum to 100% due to rounding error.

Table 2

E-cigarette and tobacco cigarette use behavior

	E-cigarettes			Tobacco cigarettes		
	Median	IQR	Range	Median	IQR	Range
Use duration (years) ^a	1	1–2	0.25–6	10	5–16	0.25–53
Days used per week, prior to e-cigarettes, ^b	–	–	–	7	6–7	1–7
Days used per week, past 30 days ^c	4	2–7	1–7	7	4–7	1–7
Times used per day ^d , prior to e-cigarettes ^{bde}	–	–	–	10	5–20	1–50
Times used per day ^d , past 30 days	5	2–10	1–200	7	3–13	1–40
Estimated puffs per bout	6	4–10	1–100	14	10–20	3–50
Nicotine Dependence (FTCD score)	2	1–4	1–9	3	1–5	0–9
Quit intent (months) ^f	6	3–10	0–12	5	3–8	0–12

Note. IQR = interquartile range, FTCD = Fagerström Test for Cigarette Dependence.

^aE-cigarette use duration data are missing for 5 participants (all reported smoking for at least 3 months to qualify for the survey).

^bData on tobacco cigarette smoking rates (cigarettes per day, days smoked per week prior to e-cigarettes) are missing from two participants.

^cData on days vaped per week are missing from one participant.

^dTimes used per day = cigarettes per day for tobacco cigarettes and ‘bouts’ per day (defined as an instance of at least one puff or vape) for e-cigarettes.

^eData on e-cigarettes used per day prior to initiation of tobacco cigarette smoking are not included for the single participant who reported this pattern of use.

^fA subsample of participants intended to quit e-cigarettes ($n = 127$) and tobacco cigarettes ($n = 254$) in the next 12 months.

Table 3

E-cigarette and tobacco dependence and craving

	E-cigarettes	Tobacco cigarettes
FTCD Level		
0–2 (Very low)	62%	42%
3–4 (Low)	21%	25%
5 (Moderate)	8%	13%
6–7 (High)	6%	17%
8–10 (Very high)	3%	4%
FTCD Q1: Time to first cigarette/use		
Within 5 minutes	7%	13%
6–30 minutes	13%	38%
31–60 minutes	12%	19%
After 60 minutes	68%	30%
FTCD Q2: Difficult to abstain when use is restricted (Yes)	16%	27%
FTCD Q3: Use time hate the most to give up		
First one in the morning	19%	50%
All others	81%	50%
FTCD Q4: Times used/cigarettes per day		
10 or less	76%	68%
20 to 30	14%	25%
21 to 30	6%	5%
31 or more	4%	1%
FTCD Q5: Use most frequently right after waking? (Yes)	19%	38%
FTCD Q6: Smoke/Use when ill? (Yes)	100%	76%
Strong cravings to smoke/vape? (Yes)	21%	76%
Ever smoked/vaped daily? (Yes)	47%	86%

Note. FTCD = Fagerström Test for Cigarette Dependence. Percentages may not sum to 100% due to rounding error.

Spearman correlations between duration or frequency of use and product use behavior for e-cigarettes and tobacco cigarettes.

Table 4

	E-cigarettes		Tobacco cigarettes	
	Use duration (years)	Days vaped/week (past 30d)	Use duration (years)	Days smoked/week (past 30d)
E-cigarettes				
Use duration (years)	-	0.02	0.19 ^{***}	0.02
Days vaped/week (past 30d)	0.02	-	-0.03	-0.03
Times used/day	0.03	0.48 ^{***}	0.01	-0.10
Estimated puffs/bout	0.02	0.05	-0.06	0.01
Modified FTCD score	0.04 [*]	0.23 ^{***}	0.01	-0.11 [*]
Tobacco cigarettes				
Use duration (years)	0.19 ^{***}	-0.03	-	0.34 ^{***}
Days smoked/week (past 30d)	0.02	-0.03	0.34 ^{***}	-
Cigarettes/day	0.01	-0.12 [*]	0.52 ^{***}	0.64 ^{***}
Cigarettes/day prior to e-cigarettes	0.01	0.11 [*]	0.53 ^{***}	0.41 ^{***}
Cigarettes/day change score	-0.01	-0.37 ^{***}	-0.15 [*]	0.11 [*]
Days smoked/week prior to e-cigarettes	0.05 [*]	0.19 ^{***}	0.36 ^{***}	0.62 ^{***}
Days smoked/week change score	0.02	-0.22 ^{***}	0.03	0.52 ^{***}
Estimated puffs/bout	-0.02	-0.01	0.20 ^{***}	0.20 ^{***}
FTCD score	0.02	0.05 [*]	0.45 ^{***}	0.43 ^{***}

Note FTCD = Fagerström Test for Cigarette Dependence. Change score = current use minus use prior to e-cigarette initiation.

* $p < .05$;

** $p < .01$;

*** $p < .001$

Table 5

Other tobacco products used in the past 30 days.

	<i>%n</i>	<i>Median days used</i>	<i>IQR</i>
Hookah	52%	2	1–4
Cigars	40%	2	1–4
Bidis/Cloves	24%	2	1–4
Cigarillos	22%	2	2–5
Pipe Tobacco	14%	5	2–24
Little Cigars	13%	2	1–3
Snus	9%	2.5	1–4
Chew	8%	6	1–10
Snuff	6%	3	1–16

Note. Data represents distribution and frequency of other tobacco product use in dual users reporting any other product use ($n=141$, 40%).

Table 6

Reported reasons for use of e-cigarettes

	Select all that apply	Select most important reason
I believe it is less harmful to my health than regular cigarettes	64%	25%
To cut down smoking tobacco in preparation for a quit attempt	40%	21%
To be able to deal with situations where I can't smoke (e.g., at work, in a restaurant)	45%	13%
To quit smoking or avoid relapsing	34%	7%
To deal with cravings for tobacco	57%	5%
I believe it is less harmful to others	52%	5%
With an e-cigarette, it is easier to just smoke one or a few puffs at a time rather than a whole cigarette	45%	5%
I can breathe easier for feel more fit	30%	5%
To avoid having to go outside to smoke	43%	4%
E-cigarettes are cheaper than regular cigarettes	27%	3%
I prefer the taste of an e-cigarette	22%	2%
To cut down smoking tobacco with no intention to quit	12%	2%
Other (e.g., prefer the smell, reduce stress)	3%	2%
To avoid withdrawal from tobacco	35%	1%
To increase my ability to concentrate	8%	1%
I can't stop using it	1%	0%

Note. Categories are sorted by “Select most important reason.”

Table 7

Reported perceived harmfulness of e-cigarettes, tobacco cigarettes, and other products.

Beliefs	E-Cigarettes			Tobacco Cigarettes		
	Median	IQR	Range	Median	IQR	Range
Risk harming self	5	3-6	0-10	9	8-10	0-10
Risk harming other	2	0-4	0-10	7	6-9	0-10
Accuracy of media representation	5	4-7	0-10	5	5-7	0-10
	<i>True</i>	<i>False</i>	<i>Don't Know</i>	<i>True</i>	<i>False</i>	<i>Don't Know</i>
Safe for human use	49%	30%	20%	11%	85%	3%
Potentially dangerous or harmful	52%	26%	22%	93%	5%	2%
This product would not be sold commercially if it were not safe to use	21%	67%	12%	7%	86%	7%
Product is regulated by the Food and Drug Administration	16%	36%	47%	41%	23%	36%

Comparison Product	E-cigarettes somewhat more harmful		Both products about the same		Product somewhat more harmful		Product much more harmful	
	E-cigarettes much more harmful	0%	Both products about the same	12%	Product somewhat more harmful	30%	Product much more harmful	57%
Tobacco cigarettes	0%	0%	12%	12%	30%	30%	57%	57%
NRT	3%	12%	59%	59%	15%	15%	10%	10%
Other medications	3%	13%	37%	37%	27%	27%	21%	21%

Note. IQR = interquartile range. NRT = nicotine replacement therapy, e.g. nicotine gum, patch, lozenge, inhaler, or nasal spray. Other medications refer to smoking cessation medications, e.g., Varenicline/Chantix or Bupropion/Zyban/Wellbutrin. Risk of harm was as based on an 11-point Likert-type scale from 0 (no risk) to 10 (extreme risk). Accuracy of media representation was based on an 11-point Likert-type scale from 0 (not at all accurate) to 10 (extremely accurate). Percentages may not sum to 100% due to rounding error.